Most biotech companies still split into two camps: avoid paid media entirely and hand market share to competitors, or run generic campaigns that burn budget on unqualified audiences. Performance marketing for pharma takes regulatory fluency, precise physician and patient targeting, and creative that converts inside compliance boundaries – not despite them.
The Problem
Generic digital agencies still don't understand pharma compliance
Your agency runs strong consumer campaigns, but they've never navigated fair balance requirements, ISI placement on digital units, or the line between branded and unbranded pharma messaging. Every ad that violates FDA guidance is a warning letter waiting to happen. Every concept killed in medical-legal review because the agency guessed at the rules is wasted development time you don't get back.
Physician targeting still requires data and channel expertise most teams lack
Reaching prescribers through paid media isn't like targeting consumers. NPI-based targeting, medical journal placements, and conference-adjacent campaigns require data partnerships and platform knowledge specific to healthcare media. Most performance marketing teams have never built an HCP targeting strategy, so they default to broad LinkedIn campaigns that reach office managers instead of prescribers.
Patient awareness campaigns still fight a measurement problem
You can't track patient conversions the way you track SaaS signups. HIPAA constraints limit pixel-based tracking, and prescription data carries real attribution lag. Most biotech companies either can't prove paid media ROI, so budgets get cut at the next planning cycle, or they lean on vanity metrics that overstate impact. Without measurement infrastructure built for these constraints, the investment stays permanently undervalued.
How We Help
Our initial assessment looks at your paid media opportunity across three audience segments: physicians (branded and unbranded HCP campaigns), patients (disease awareness and branded patient campaigns), and payers (market access and value messaging). We audit current spend, review your compliance process, and flag the targeting and measurement gaps holding back performance.
Strategy development builds channel-specific plans for each audience with compliance built in from day one, not bolted on during review – this is where our [growth strategy](/services/strategy/) work starts. Physician campaigns use NPI-targeted placements, medical journal networks, and conference-adjacent digital buys. Patient campaigns segment by disease-awareness stage and use creative that drives action within ISI and fair balance rules. Payer-directed campaigns lead with health economics messaging through targeted channels.
Execution runs the full campaign lifecycle: [creative production](/services/creative/), medical-legal review coordination, media buying, and optimization. Our team knows how pharma ad review works, so concepts are built to survive MLR from the first draft – that kills the create-review-reject-recreate cycle that makes most in-house teams dread paid media. We adjust targeting and creative against performance data inside compliance boundaries, not around them.
[Measurement and analytics](/services/measurement/) builds pharma-appropriate attribution that accounts for HIPAA constraints and prescription data lag. We tie paid media activity to commercial metrics that matter – physician engagement depth, patient enrollment inquiries, prescription lift in targeted geographies – instead of click-through rates that say nothing about commercial impact. Companies running a parallel [content marketing program for biotech and pharma](/services/content-marketing-for-biotech-pharma/) typically see paid media perform better, since organic and paid reinforce the same physician and patient messaging.
What we deliver
- Compliant campaign architecture – branded and unbranded strategies with MLR-ready creative frameworks
- Physician targeting strategy – NPI-based campaigns across medical and professional channels
- Patient awareness programs – disease education and branded campaigns within regulatory guardrails
- Pharma attribution model – measurement framework built for HIPAA constraints and prescription data lag
Performance marketing in pharma isn't hard because of compliance. It's hard because most agencies don't know how to be creative within compliance. The companies taking market share through paid media aren't bending rules – they're building campaigns that are compliant by design, not compliant by accident.
Our Methodology
Our performance marketing methodology for biotech starts with compliance infrastructure, not campaign creative. Phase one audits your medical-legal review process, identifies bottlenecks, and sets creative frameworks that pass MLR consistently. We also stand up pharma-appropriate measurement infrastructure: HIPAA-compliant tracking, prescription data partnerships, and attribution models that account for the lag between paid media exposure and prescribing behavior.
Phase two launches initial campaigns across priority audience segments with controlled budgets. We test creative concepts, targeting approaches, and channel strategies to set performance baselines before scaling spend. Each campaign follows a compliance-first process: brief development, MLR pre-alignment, creative production, formal review, launch.
Phase three scales proven campaigns and optimizes continuously. Budget allocation shifts based on performance data across physician, patient, and payer segments. Quarterly strategy reviews reassess channel mix, creative refresh needs, and measurement model accuracy – pharma media buying patterns shift often enough that a plan built in Q1 rarely survives untouched to Q4.
How We Work
Performance marketing engagements for biotech typically run 6-12 months, with the first 45 days focused on compliance infrastructure, measurement setup, and initial campaign development. We audit your current paid media activity, establish compliant creative workflows, and build the attribution models needed to measure pharma-specific outcomes.
Months 2-3 launch initial campaigns with controlled budgets across priority audience segments. We test messaging, targeting, and channel strategy to establish baselines. Creative moves through your MLR process with our team managing revisions and approvals – familiarity with pharma review typically cuts review cycles down.
Months 4-12 scale proven campaigns, launch new audience segments, and optimize continuously. We manage monthly budget allocation, creative refreshes, and performance reporting. Weekly reviews track campaign-level metrics; monthly strategy sessions connect paid media performance to commercial outcomes.
Your team provides clinical accuracy review and MLR coordination. We handle strategy, creative development, media buying, and optimization. Most clients allocate 1-2 hours per week of internal time to campaign oversight and approvals.
- Physician engagement – HCP reach and engagement through compliant targeted campaigns
- Patient awareness – disease education and branded campaign performance within regulatory guidelines
- Marketing efficiency – reduced cost per qualified interaction through pharma-optimized targeting
If your biotech & pharma company needs performance marketing leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does performance marketing cost for biotech companies?
Management fees typically range from $15K-$40K per month plus media spend. Total investment depends on your audience segments (HCP only vs. HCP plus patient plus payer), competitive intensity, and geographic scope. Media budgets for initial testing start at $20K-$50K per month and scale based on performance. Compared to the cost of expanding a field team or adding sales reps, digital performance marketing often delivers a better cost per physician engagement.
How do you handle FDA compliance in paid media campaigns?
Compliance is built into our creative process from the start, not reviewed at the end. We design concepts within known regulatory parameters – fair balance requirements, ISI placement rules, branded vs. unbranded distinctions. Our creative briefs already account for compliance, so concepts entering MLR are aligned with regulatory expectations before the first review. That typically reduces review cycles and rejection rates compared to agencies learning pharma rules on the job.
How long before we see results from pharma performance marketing?
Initial engagement metrics – physician reach, click-through rates, patient awareness – appear within 30-60 days. Commercial impact metrics like prescription lift, physician engagement quality, and patient enrollment inquiries take 3-6 months because of the natural lag between awareness and prescribing behavior. We set leading indicators that predict commercial impact while waiting on downstream conversion data.
What makes Winston Francois different from a pharma digital agency?
Most pharma agencies treat compliance as an obstacle that limits creativity. We treat it as a design constraint that shapes creative strategy from the brief forward. Our team combines performance marketing expertise with pharma regulatory knowledge, so campaigns are built to perform within compliance boundaries from the start. We also connect paid media performance to commercial outcomes, not just digital metrics.
How do you measure performance marketing ROI under HIPAA constraints?
We build attribution models designed around pharma's measurement limits: HIPAA-compliant tracking infrastructure, prescription data partnerships for geographic lift analysis, physician engagement scoring, and patient enrollment correlation analysis. We never rely on pixel-based conversion tracking for clinical outcomes – instead we build proxy metrics validated against real prescribing data.
What type of biotech company should invest in performance marketing?
Commercial-stage companies with approved products benefit most immediately, since paid media directly supports physician awareness and patient enrollment. Late-stage clinical companies benefit from unbranded disease awareness campaigns that build market readiness before launch. Early-stage companies should focus on corporate brand and investor marketing, not patient or physician campaigns. The first step is a paid media audit to assess your opportunity and compliance readiness.
